Drugs / CMAB304
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01459887 | Sep 2006 → Dec 2010 | diffuse large B-cell lymphoma | Shanghai CP Guojian Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMAB304 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01459887 ↗ |
| Known as | Retuxira | “CMAB304(Retuxira), the chimeric monoclonal antibody is designed to targeted against CD20 for treatment of lymphoma diseases.” NCT01459887 ↗ |
| Modality | Monoclonal antibody | “CMAB304(Retuxira), the chimeric monoclonal antibody is designed to targeted against CD20 for treatment of lymphoma diseases.” NCT01459887 ↗ |